Cullinan Therapeutics, Inc.
CGEMHeld by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase2 readout (CLN-081): Jan 2026. Short interest: 20.3% of float.
Held by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase2 readout (CLN-081): Jan 2026. Short interest: 20.3% of float.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.